Journal article
Predicting Alzheimer disease from a blood-based biomarker profile
SC Burnham, CC Rowe, D Baker, AI Bush, JD Doecke, NG Faux, SM Laws, RN Martins, P Maruff, SL Macaulay, S Rainey-Smith, G Savage, D Ames, CL Masters, W Wilson, VL Villemagne
Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2016
Abstract
Objective: We assessed a blood-based signature, which previously demonstrated high accuracy at stratifying individuals with high or low neocortical β-amyloid burden (NAB), to determine whether it could also identify individuals at risk of progression to Alzheimer disease (AD) within 54 months. Methods: We generated the blood-based signature for 585 healthy controls (HCs) and 74 participants with mild cognitive impairment (MCI) from the Australian Imaging, Biomarkers and Lifestyle Study who underwent clinical reclassification (blinded to biomarker findings) at 54-month follow-up. The individuals were split into estimated high and low NAB groups based on a cutoff of 1.5 standardized uptake val..
View full abstractGrants
Funding Acknowledgements
Core funding for the study was provided by the CSIRO Flagship Collaboration Fund and the Science and Industry Endowment Fund in partnership with Edith Cowan University, Mental Health Research Institute, Alzheimer's Australia, National Ageing Research Institute, Austin Health, Macquarie University, Cogstate Ltd., Hollywood Private Hospital, and Sir Charles Gardner Hospital. The study also receives funding from the National Health and Medical Research Council (NHMRC), the Dementia Collaborative Research Centres program, the McCusker Alzheimer's Research Foundation, and Operational Infrastructure Support from the Government of Victoria. N.G. Faux is supported by a National Health and Medical Research Council training fellowship. S.M. Laws, J.D. Doecke, and W. Wilson receive financial support from the Cooperative Research Centre (CRC) for Mental Health, an Australian Government Initiative. A. I. Bush is supported by the NHMRC, by a program grant, and an Australian Fellowship. V.L. Villemagne is supported by an NHMRC Senior Research Fellowship.